Kalaris Therapeutics Ownership | Who Owns Kalaris Therapeutics?

Kalaris Therapeutics Ownership Summary

Kalaris Therapeutics is owned by 80.68% institutional investors, 9.90% insiders, and 9.42% retail investors. Samsara biocapital is the largest institutional shareholder, holding 56.54% of KLRS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 0.77% of its assets in Kalaris Therapeutics shares.

KLRS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Kalaris Therapeutics	80.68%	9.90%	9.42%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Samsara biocapital	12.95M	56.54%	$74.71M
Rtw investments, lp	1.30M	5.68%	$7.50M
Paradigm biocapital advisors lp	700.00K	3.06%	$4.04M
Alyeska investment group	572.69K	2.50%	$3.27M
Tang capital management	418.24K	2.24%	$2.42M
Siren	435.80K	1.90%	$2.51M
Ikarian capital	360.00K	1.57%	$2.08M
Vanguard group	292.79K	1.57%	$2.47M
Propel bio management	295.77K	1.29%	$1.72M
Raymond james financial	118.89K	0.52%	$685.98K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Samsara biocapital	12.95M	7.26%	$74.71M
Propel bio management	295.77K	1.08%	$1.72M
Ikarian capital	360.00K	0.17%	$2.08M
Tang capital management	418.24K	0.09%	$2.42M
Paradigm biocapital advisors lp	700.00K	0.08%	$4.04M
Rtw investments, lp	1.30M	0.07%	$7.50M
Siren	435.80K	0.07%	$2.51M
Velan capital investment management lp	18.00K	0.07%	$103.86K
Stonepine capital management	20.40K	0.05%	$117.71K
Wealthtrust asset management	12.42K	0.04%	$71.64K

Top Buyers

Holder	Shares	% Assets	Change
Propel bio management	295.77K	1.08%	253.72K
Alyeska investment group	572.69K	0.01%	169.14K
Vanguard group	292.79K	-	89.74K
Goldman sachs group	110.50K	0.00%	76.20K
Simplify asset management	87.43K	0.01%	67.35K

Top Sellers

Holder	Shares	% Assets	Change
Octagon capital advisors lp	-	-	-360.00K
Gilead sciences	-	-	-317.79K
Ecor1 capital	-	-	-201.72K
Redmile group	-	-	-82.95K
683 capital management	45.00K	0.01%	-35.59K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	36.72K	0.00%	36.72K	$211.86K
Stonepine capital management	20.40K	0.05%	20.40K	$117.71K
Velan capital investment management lp	18.00K	0.07%	18.00K	$103.86K
Independent advisor alliance	14.23K	0.00%	14.23K	$82.11K
Wealthtrust asset management	12.42K	0.04%	12.42K	$71.64K

Sold Out

Holder	Change
Eversource wealth advisors	-30.00
Farther finance advisors	-33.00
Coldstream capital management	-208.00
Xtx topco	-10.90K
Walleye capital	-11.22K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	57	11.76%	18,478,771	2.68%	80	0.87%	31	-8.82%	7	-
Dec 31, 2025	19	-38.71%	748,273	-94.34%	4	0.08%	11	-35.29%	4	-20.00%
Sep 30, 2025	11	-62.07%	388,919	-97.09%	2	0.04%	7	-41.67%	2	-71.43%
Jun 30, 2025	29	-6.45%	13,362,268	-3.69%	329	5.99%	12	-61.29%	7	-
Mar 31, 2025	31	-	13,874,350	-	74	-	31	-	-	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	176.73K	0.77%	-
Vanguard Institutional Extnd Mkt Idx Tr	72.62K	0.32%	-
Simplify Propel Opportunities ETF	57.76K	0.25%	-
Fidelity Extended Market Index	36.62K	0.16%	2.64K
Bridgeway Ultra-Small Company Market	22.50K	0.10%	-
Fidelity Nasdaq Composite Index	16.83K	0.07%	-
Fidelity Total Market Index	9.88K	0.04%	-
Spartan Extended Market Index Pool F	9.58K	0.04%	1.48K
Fidelity Series Total Market Index	9.57K	0.04%	716.00
Goldman Sachs Absolute Ret Trckr Instl	8.95K	0.04%	-11.10K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 20, 2026	AKKARAJU SRINIVAS		Buy	$1.18M
Mar 20, 2026	Hagen Brett R	Chief Accounting Officer	Sell	$12.87K
Dec 18, 2025	AKKARAJU SRINIVAS		Buy	$5.00M
Mar 26, 2025	Hagen Brett R	Chief Accounting Officer	Sell	$8.14K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	1	-
2026 Q1	-	1
2025 Q4	1	-
2025 Q2	-	-
2025 Q1	-	1

KLRS Ownership FAQ

Who Owns Kalaris Therapeutics?

Kalaris Therapeutics shareholders are primarily institutional investors at 80.68%, followed by 9.90% insiders and 9.42% retail investors. The average institutional ownership in Kalaris Therapeutics's industry, Biotech Stocks , is 35.75%, which Kalaris Therapeutics exceeds.

Who owns the most shares of Kalaris Therapeutics?

Kalaris Therapeutics’s largest shareholders are Samsara biocapital (12.95M shares, 56.54%), Rtw investments, lp (1.3M shares, 5.68%), and Paradigm biocapital advisors lp (700K shares, 3.06%). Together, they hold 65.27% of Kalaris Therapeutics’s total shares outstanding.

Does Blackrock own Kalaris Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Kalaris Therapeutics.

Who is Kalaris Therapeutics’s biggest shareholder by percentage of total assets invested?

Samsara biocapital is Kalaris Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.26% of its assets in 12.95M Kalaris Therapeutics shares, valued at 74.71M$.

Who is the top mutual fund holder of Kalaris Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Kalaris Therapeutics shares, with 0.77% of its total shares outstanding invested in 176.73K Kalaris Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools